These findings were reported in other studies showing that in patients with relapsed or refractory CLL on oral venetoclax monotherapy, both NOTCH1 and SF3B1 mutations correlate with shortened duration of response [71,73]. This evidence concerns the gene NOTCH1 and B-cell chronic lymphocytic leukemia.